Lung Cancer Surgery in Sarcopenia Patients With Old Age

NCT05346185 | Active Not Recruiting

• 1 other identifier: 800-20210011
• Study Type: observational
• Target: 400
• Locations: 1 country
• Sites: 1

Brief Summary

The presence of sarcopenia before lung resection surgery might be an important factor of short-term and long-term prognosis in lung cancer patients. Through this study, investigators plan to demonstrate evidence whether sarcopenia is a useful clinical biomarker for risk stratification in elderly patients undergoing lung cancer surgery.

Conditions

Sarcopenia; Lung Cancer

Keywords

sarcopenia; lung cancer; surgery; long-term survival; complication; pulmonary function; quality of life

Outcome Measures

Primary Outcomes (1)

• overall survival

  survival status during the follow-up after the lung cancer surgery

  5 years after the day of lung cancer surgery

Secondary Outcomes (10)

• recurrence free survival

  up to 5 years after the day of lung cancer surgery

• non-cancer related mortality

  up to 5 years after the day of lung cancer surgery

• postoperative change of pulmonary function

  at postoperative 1 year, 5 year

• postoperative complication rate

  from the day of lung cancer surgery to the discharge after lung cancer surgery (up to 6 months)

• operative mortality

  from the day of lung cancer surgery to the discharge after lung cancer surgery (up to 6 months)

Eligibility Criteria

• Age: 70 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients above the age of 70 who are planning to undergo curative surgery for proven lung cancer or pulmonary nodules suspected for lung cancer

You may qualify if:

• Patients planning to perform curative surgery for confirmed lung cancer and pulmonary nodules suspected for lung cancer
• Patients or legal representatives who could understand and write written consent prior to the initiation of the clinical trial and are able to comply with the requirements for the clinical trial

You may not qualify if:

• Patients with treatment history for lung cancer or other solid cancer within 5 years (except patients with adenocarcinoma in situ for lung cancer)
• Patients who need simultaneous surgery with lung caner surgery for other accompanying diseases
• Patients who are not eligible to participate in the study judged by the researcher

Sponsors & Collaborators

• Seoul National University Hospital: lead

Study Sites (1)

Seoul National University Hospital

Seoul, 03080, South Korea

Location

Related Publications (1)

• Woo HS, Na KJ, Yun T, Park JH, Na B, Park S, Lee HJ, Kang CH, Kim YT, Park IK. Impact of sarcopenia on early surgical outcomes in elderly patients following lung cancer surgery: a prospective cohort study. J Thorac Dis. 2025 Oct 31;17(10):7838-7852. doi: 10.21037/jtd-2025-1375. Epub 2025 Oct 29.

  PMID: 41229782 DERIVED

MeSH Terms

Conditions

Sarcopenia; Lung Neoplasms

Condition Hierarchy (Ancestors)

Muscular Atrophy; Neuromuscular Manifestations; Neurologic Manifestations; Nervous System Diseases; Atrophy; Pathological Conditions, Anatomical; Pathological Conditions, Signs and Symptoms; Signs and Symptoms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Study Officials

• In Kyu Park, MD, PhD

  Seoul National University Hospital, Department of Thoracic and Cardiovascular Surgery

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 5 Years
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: April 20, 2022
• First Posted: April 26, 2022
• Study Start: April 13, 2021
• Primary Completion (Estimated): June 30, 2028
• Study Completion (Estimated): June 30, 2028
• Last Updated: January 9, 2026

Record last verified: 2026-01

Locations

KR (1)